trial

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

NCTId NCT01668797
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 524 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2015-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
524 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2012-10
Primary completion
2015-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
Quintiles, Inc.Collaborator

Investigators

1
Aleksandar Skuban, M.D.Study Director

Sites

0 total

Linked catalysts

1
Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance T — primary completion2015-01

Facts & assertions

4 sourced
Enrollment
524
Phase
PHASE3
Primary Completion Date
2015-01
Status
COMPLETED
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
collaborator
Quintiles, Inc.
company
indication
Acute Schizophrenia
indication
investigator
Aleksandar Skuban, M.D.
person